Study:
A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma
Rationale:
Giving chemotherapy before an autologous stem cell transplant stops the growth of
tumor cells by stopping them from dividing or killing them. After treatment, stem cells are
collected from the patient`s blood and/or bone marrow and stored. More chemotherapy is given
to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to
the patient to replace the blood-forming cells that were destroyed by the chemotherapy.
Radiation therapy uses high energy x-rays to kill tumor cells. Giving radiation therapy
after combination chemotherapy and/or autologous stem cell transplant may kill any remaining
tumor cells.
Purpose:
This phase III trial is studying the side effects and how well giving combination
chemotherapy together with autologous stem cell transplant and/or radiation therapy works in
treating young patients with extraocular retinoblastoma..
Study Status: Recruiting
Recruiting:
Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100
| Condition |
Intervention |
Phase |
|
Retinoblastoma |
Biological: filgrastim
Drug: carboplatin
Drug: cisplatin
Drug: cyclophosphamide
Drug: etoposide
Drug: thiotepa
Drug: vincristine sulfate
Procedure: autologous bone marrow transplantation
Procedure: autologous hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy |
Phase 3 |
Verified by
Children`s Oncology Group
November, 2012
Sponsored by: Children`s Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00554788
Study Type: Interventional
Study Design: Allocation: Non-Randomized, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Ira Dunkel, MD., Study Chair
Eric F. Grabowski, MD, ScD.,